Background incidence of liver chemistry abnormalities in pediatric clinical trials for conditions with and without underlying liver disease

Regulatory Toxicology and Pharmacology

Volumn 62, Issue 2, 2012, Pages 329-335

  Stirnadel, Heide A ^a   Bains, Chanchal ^a   Lakshmi, Mynepalli ^b   Pandey, Rakesh ^b   Webb, David J ^a   Irizarry, Michael C ^c   Hunt, Christine M ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GlaxoSmithKline Pharmaceuticals Ltd   (India)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Drug induced liver injury; Epidemiology; Hy's law; Liver function tests; Pediatric clinical trials

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BECLOMETASONE DIPROPIONATE; BILIRUBIN; CEFALEXIN; LAMIVUDINE; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; BILIRUBIN BLOOD LEVEL; CHILD; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPETIGO; INCIDENCE; INFANT; LIVER DISEASE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALARIA; MALE; META ANALYSIS; OUTCOMES RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; REFERENCE VALUE; SCHOOL CHILD; TOXIC HEPATITIS;

ADOLESCENT; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; BILIRUBIN; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LIVER DISEASES; MALE;

HEPATITIS B VIRUS;

EID: 84857358403     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2011.10.013     Document Type: Article

References (17)

1. Brun A., Pitchumoni C.S. Biliary diseases in HIV. Pract. Gastroenterol. 2010, 34:24-32.
2. Cai Z., Christianson A.M., Stahle L., Keisu M. Re-examining transaminase elevations in phase 1 clinical trials: the importance of baseline and change from baseline. Eur. J. Clin. Pharmacol. 2009, 65:1025-1035.
3. Della Negra M., Queiroz W., Taveras C.J.R., Lian Yu.Ching., De Fatima Araujo M., Melhen M.S.C., Martins M.C. Liver disorders in paediatric AIDS patients. Pediatr. AIDS HIV Infect. 1993, 4:222-226.
4. Dufour D.R., Lott J.A., Nolte F.S., Gretch D.R., Koff R.S., Seeff L.B. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin. Chem. 2000, 46:2027-2049.
5. FDA, 2009. US Food and Drug Administration Guidance for Industry, July 2009, entitled: Drug-Induced Liver Injury: Premarketing Clinical Evaluation. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf.
6. Fraser A., Longnecker M.P., Lawlor D.A. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology 2007, 133:1814-1820.
7. Gray D., Nuttall J., Lombard C., Davies M., Workman L., Apolles P., Eley B., Cotton M., Zar H. Low rates of hepatotoxicity in HIV-infected children on anti-retroviral therapy with and without isoniazid prophylaxis. J. Trop. Pediatr. 2010, 56:159-165.
8. Ioannou G.N., Boyko E.J., Lee S.P. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am. J. Gastroenterol. 2006, 101:76-82.
9. Katz D.A., Isaacson J.D., Han L., Drajesk J.F., Comer G.M., Heath-Chiozzi M.E. Clinical observation of liver chemistry abnormalities in asthmatics. Curr. Drug Saf. 2009, 4:173-180.
10. Larson A.M., Polson J., Fontana R.J., Davern T.J., Lalani E., Hynan L.S., Reisch J.S., Schiødt F.V., Ostapowicz G., Shakil A.O., Lee W.M. Acetaminophen-induced acute liver failure: results of a United States multicenter prospective study. Hepatology 2005, 42:1364-1372. Acute Liver Failure Study Group.
11. Le J., Nguyen T., Law A.V., Hodding J. Adverse drug reactions among children over a 10-year period. J. Pediatr. 2006, 118:555-562.
12. Lin, X., Parks, D., Zhu, L., Lee, K., Menius, A., Curtis, L., Steel, H., Rut, A., Mooser, V., Cardon, L. Truncated Robust Distance for Clinical Laboratory Safety Data Monitoring and Assessment. J. Biopharm. Stat. in press.
13. Schwimmer J.B., Dunn W., Norman G.J., Pardee P.E., Middleton M.S., Kerkar N., Sirlin C.B. Safety study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 2010, 138:1357-1364.
14. Squires R.H., Shneider B.L., Bucuvalas J., Alonso E., Sokol R.J., Narkewicz M.R., Dhawan A., Rosenthal P., Rodriguez-Baez N., Murray K.F., Horslen S., Martin M.G., Lopez M.J., Soriano H., McGuire B.M., Jonas M.M., Yazigi N., Shepherd R.W., Schwarz K., Lobritto S., Thomas D.W., Lavine J.E., Karpen S., Ng V., Kelly D., Simonds N., Hynan L.S. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J. Pediatr. 2006, 148:652-658.
15. Strauss R.S., Barlow S.E., Dietz W.H. Prevalence of abnormal serum aminotransferease values in overweight and obese adolescents. J. Pediatr. 2000, 136:727-733.
16. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepi. Drug Saf. 2006, 15:241-243.
17. Weil J.G., Bains C., Linke A., Clark D.W., Stirnadel H.A., Hunt C.M. Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease. Reg. Tox. Pharmacol. 2008, 52:85-88.